Oct. 10, 2013
/PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that data from the ongoing Phase I clinical trial of its mitochondrial inhibitor drug candidate ME-344 in patients with refractory solid tumors will be presented at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in
As reported in the abstract of the presentation, eight of the 23 patients evaluable for efficacy (35%) achieved disease control, including one confirmed partial response (PR) in a patient with refractory small cell lung cancer (duration 52+ weeks) and seven patients with prolonged stable disease (SD) ranging from 8 to 40+ weeks. The maximum tolerated dose was established at 10 mg/kg delivered on a weekly schedule. Dose limiting toxicity of Grade 3 neuropathy was observed at 15 mg/kg and 20 mg/kg.
Detailed results from the trial will be presented on
Sunday, October 20, 2013
12:30 p.m. Eastern time
from Exhibit Hall C-D of the Hynes Convention Center. The abstract, entitled "ME-344, a novel mitochondrial oxygenase inhibitor: Results from a first-in-human Phase I study," is now available online at
ME-344 is MEI Pharma's next-generation mitochondrial inhibitor drug candidate and an active metabolite of NV-128, the Company's first-generation compound. In
, M.D., Department of Obstetrics, Gynecology and Reproductive Sciences at
Yale University School of Medicine
, presented data at the American Association for Cancer Research (AACR) Annual Meeting showing the ability of ME-344 to decrease tumor burden and delay recurrence in a pre-clinical
model of recurrent epithelial ovarian cancer, the most lethal of all gynecologic malignancies. In
, Dr. Alvero also presented data at AACR from a pre-clinical study of NV-128 demonstrating its ability to induce mitochondrial instability, ultimately leading to cell death in otherwise chemotherapy-resistant ovarian cancer stem cells. These results were later published in the
Molecular Cancer Therapeutics
. In additional pre-clinical studies, ME-344 demonstrated superior anti-tumor activity against a broad range of human cancer cell lines compared to NV-128.
MEI Pharma owns exclusive worldwide rights to ME-344.